Children and Adolescents with Cancers Harboring V600 mutation.
Conditions
Brief summary
AEs, SAE, clinically significant changes in laboratory values and vital signs.
Detailed description
Serial measurements of height, weight, skeletal maturation, sexual maturation and cardiac function., Disease specific clinical benefit, as determined by investigator using institutional standard of care.
Sponsors
Novartis Pharma AG
Eligibility
Sex/Gender
All
Age
0 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AEs, SAE, clinically significant changes in laboratory values and vital signs. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serial measurements of height, weight, skeletal maturation, sexual maturation and cardiac function., Disease specific clinical benefit, as determined by investigator using institutional standard of care. | — |
Countries
Belgium, Czechia, Denmark, Finland, France, Germany, Italy, Netherlands, Spain, Sweden
Outcome results
None listed